Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

From the editor

Humphrey Hodgson
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.13-3-219
Clin Med June 2013
Humphrey Hodgson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Apocalypse – when?

Most physicians (listening, no doubt, to BBC Radio 4 one early March morning) will have been struck by Dame Sally Davies’ use of the ‘A-word’ as she described the prospect of a post-antibiotic era in which the development of resistance by currently susceptible micro-organisms turns back the clock to the early 20th century.1 The second part of her annual report on the health of the nation, published on 11 March, describes the challenges from both established and emerging diseases.2 It highlights the relative lack of investment in antibiotic development and charts the rate of emergence of new diseases. One of the most striking illustrations in the report is a timeline for the recognition of new diseases since 1980 – coincidentally the same year the last new class of antibiotics was discovered and developed. The report comprises both the chief medical officer’s advice to the government and a series of authoritative reports on which she has based that advice – in particular, highlighting the risks and challenges to people in different age groups. Bacterial infections and the emerging dominance of resistant Gram-negative organisms constitute a growing menace in adults.

The barriers to the development of new antibiotics have been well rehearsed – the cost of development scarcely stacks up against the payback, since a highly successful new antibiotic would only be prescribed in courses lasting from a few days to weeks. The contrast with a successful lipid-lowering drug, a drug for arthritic pain or an antihypertensive is striking. The contrast with many anti-viral drugs is also marked; when suppression rather than cure is the outcome, as in HIV and HBV for example, extended courses offer the prospect of greater return on investment. Such considerations open up the question of what alternatives to the pharmaceutical company model of innovation and drug discovery might be encouraged.

Dame Sally advocates further actions by the Innovative Medicines Initiative (IMI), a private–public partnership aimed at improving drug development, currently backed by €2 billion (half from the European Commission and half from members of the European Federation of Pharmaceutical Industries and Associations).2 Its rather tweely named ND4BB (New Developments for Bad Bugs) programme may dispose up to €400 million. Its €200 million COMBACTE project brings together three major pharmaceutical companies – GlaxoSmithKline Research and Development, AstraZeneca AB and Janssen Infectious Disease Diagnostics BVBA – with 16 European universities and research organisations, to design and implement improvements to clinical trials for antibiotics. No doubt the UK is well-represented among these international academic and research partners, one would have thought. All credit to the North Bristol NHS Trust – the only UK institution in the list.3

While the concentration on improving and speeding up clinical trials (topic 1 of the IMI) is, of course, welcome, physicians and academic researchers might wish for an additional scientific initiative to discover new drugs. Discovery and development of new drugs combating Gram-negative infections remains a future topic on the ND4BB suggested architecture.4 However, there is already one – albeit smaller – IMI programme directly addressing bacterial susceptibility. TRANSLOCATION is aimed at increasing understanding of how to get antibiotics into multi-resistant Gram-negative bacteria. Here at least two of the fourteen universities, research organisations etc, are British (step forward Newcastle and St Andrews).5

What other approaches, outside the involvement of large (and necessarily bureaucratic?) European Organisations, should be encouraged to prevent this apocalypse and, in particular, how should the UK respond? The MRC’s Infection and Immunology Board lists microbiology and microbial resistance as a key area being stimulated through the development of research partnerships and consortia. Its website highlights £4 million in 2011 for two such grants.6 It is more difficult to discern how much funding in total is directed at front-line in vitro research into microbial metabolism – both through centres such as the MRC Centre for Molecular Bacteriology and Infection, and through project-specific funding through the MRC and the Wellcome trust. However, if Dame Sally’s warnings are to be taken at face value, the funding bodies – and UK academic and clinical institutions – should be concentrating resources and enhancing priorities in this area. The history of the development of anti-HIV drugs in the 1990s in response to urgent investment shows clearly that research endeavour can be channelled to specific aims by directing research funds to the area of need. If the risks are as stated, the current response seems limited. In stimulating research on new antibiotics, the strategy of leaving the windows open in Praed Street has probably fulfilled its potential.

  • © 2013 Royal College of Physicians

References

  1. ↵
    BBC News Health. Antibiotics resistance ‘as big a risk as terrorism’ – medical chief, 2013. www.bbc.co.uk/news/health-21737844 [Accessed 5 April 2013].
  2. ↵
    1. Davies SC
    . Annual Report of the Chief Medical Officer, Volume Two, 2011, Infections and the rise of antimicrobial resistance. London: DoH, 2013. www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf [Accessed 5 April 2013].
  3. ↵
    Innovative Medicines Innitiative. Combact. Combatting Bacterial Resistance in Europe, 2013. www.imi.europa.eu/content/combacte [5 April 2013].
  4. ↵
    1. Payne D,
    2. O’Brien S
    . Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB). IMI Stakeholder Forum 2012. www.imi.europa.eu/sites/default/files/uploads/documents/SF2012/WkshpA_ppt2_Payne.pdf [Accessed 5 April 2013].
  5. ↵
    IMI Translocation. Molecular basis of the bacterial cell wall permeability, 2013. www.imi.europa.eu/content/translocation [Accessed 5 April 2013].
  6. ↵
    Medical Research Council. IIB Programme, 2013. www.mrc.ac.uk/Ourresearch/Boardpanelsgroups/IIB/Programme/index.htm#P46_3438 [Accessed 5 April 2013].
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
From the editor
Humphrey Hodgson
Clinical Medicine Jun 2013, 13 (3) 219-220; DOI: 10.7861/clinmedicine.13-3-219

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
From the editor
Humphrey Hodgson
Clinical Medicine Jun 2013, 13 (3) 219-220; DOI: 10.7861/clinmedicine.13-3-219
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Apocalypse – when?
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The past, the present, and the future: reflecting on ­medical history as we welcome new leaders
  • Targeting limited NHS resources to affect optimal care
  • Regulation needs new legislation to get lighter
Show more Editorials

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians